Peabody, MA– Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy on patients”, announced today that it will give a virtual company presentation and participate in one-on-one investor meetings at the 2022 BIO CEO & Investor Conference from February 14-17. Those looking to meet with Privo can schedule a meeting through the BIO One-on-One Partnering portal.

The presentation will focus on an introduction of the PRV platform technology’s lead assets (PRV111 and PRV211) and their respective upcoming clinical trial designs in oral cavity cancer (carcinoma and situ) and a basket study for all solid tumors. The localized targeted delivery of our nanoparticles allows the PRV platform to deliver high doses of potent chemotherapeutics while avoiding systemic side effects. This makes the platform particularly well suited for its lead indication, oral cavity cancer (OCC), which is a rare and disfiguring disease resulting in a poor quality of life due to the having no alternative treatment method to surgery. OCC is also known to acquire chemo resistance, which our efficacious nanoparticles mitigate. Privo is excited to showcase the potential of the PRV platform, a discovery that can prevent cancer from being a life changing event.

The Company’s presentation will be available on demand on the BIO CEO & Investor Conference website until March 20, 2022.

About Privo Technologies, Inc.
Privo Technologies, Inc. (Privo) is a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal mucosal cancers. Privo is headquartered in Peabody, Massachusetts. Privo’s initial focus is on oral cavity cancers for their two lead assets PRV111 and PRV211. PRV111 is a derivative of the PRV platform, a novel nanotechnology-based system that can improve the efficacy of potent anticancer drugs and significantly improving their safety through locoregional delivery. This approach eliminates needles, avoids stomach acids, significantly reduces toxic side effects of drugs, and allows for significantly higher dosing where the drugs can be most effective without the previously known side effectives– all of which have the potential to improve patient outcomes and compliance. This platform has broad potential applications for use in other mucosal cancers, including anal, colorectal, genitourinary, nasal, and skin cancers. Another derivative, PRV211, is a sterilized, rapid release chemotherapy patch that can be applied intraoperatively post-tumor resection to potentially reduce the risk of cancer recurrence.

For additional information on Privo Technologies, Inc. please visit www.privotechnologies.com.